Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Active Biotech AB And Ipsen SA Announce Completion of Recruitment of Tasquinimod Clinical Phase III Study in Prostate Cancer


Monday, 10 Dec 2012 01:30am EST 

Active Biotech AB And Ipsen SA announced that the Phase III clinical trial for tasquinimod, a compound for the treatment of prostate cancer, is successfully enrolled with over 1,200 randomized patients as planned in the clinical protocol. 

Company Quote

22.3
0.4 +1.83%
7:59am EDT